T. Rowe Price Associates, Inc. 13D and 13G filings for MoonLake Immunotherapeutics:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-14 10:45 am Sale |
2025-03-31 | 13G | MoonLake Immunotherapeutics MLTX |
T. Rowe Price Associates, Inc. | 2,974,271 4.700% |
-369,372 (-11.05%) |
Filing |
| 2025-02-14 09:44 am Purchase |
2024-12-31 | 13G | MoonLake Immunotherapeutics MLTX |
T. Rowe Price Associates, Inc. | 3,343,643 5.300% |
2,521,042 (+306.47%) |
Filing |
| 2023-02-14 12:38 pm Purchase |
2022-12-31 | 13G | MoonLake Immunotherapeutics MLTX |
T. Rowe Price Associates, Inc. | 822,601 2.100% |
822,601 (New Position) |
Filing |